Goldline Pharmaceutical Limited (BOM:544759)

Market Cap	372.86M
Revenue (ttm)	311.99M +29.9%
Net Income	41.17M +1,141.3%
EPS	5.97 +979.0%
Shares Out	9.60M
PE Ratio	6.51
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	33,000
Open	39.85
Previous Close	40.39
Day's Range	38.84 - 40.28
52-Week Range	38.84 - 60.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 8, 2026

About Goldline Pharmaceutical

Goldline Pharmaceutical Limited engages in marketing of pharmaceutical products under the Goldline brand in India. It offers goldline pharma, goldline cardinal, goldline aayushman, goldline inLife, and goldline wellness. The company serves physicians, orthopedics, ENT, chest physicians, general and specialty surgery, gastroenterology, neurology, urology, endocrinologists, cardiologists, general physicians, pediatricians, child specialists, neonatologists, intensivists, critical care consultants, and super specialty surgeons. It sells its produc...

• Industry: Drugs, Drug Proprietaries, and Druggists' Sundries
• Founded: 2004
• Country: India
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 544759

Financial Performance

In fiscal year 2026, Goldline Pharmaceutical's revenue was 311.99 million, an increase of 11.20% compared to the previous year's 280.56 million. Earnings were 41.17 million, an increase of 45.26%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jul 15, 2026

Data Sources Report a data error